Home Applications 212194 Application 212194
Type NDA
Sponsor ALNYLAM PHARMS INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 GIVLAARI GIVOSIRAN SODIUM SOLUTION;SUBCUTANEOUS EQ 189MG BASE/ML (EQ 189MG BASE/ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N212194-001 GIVLAARI GIVOSIRAN SODIUM EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2019-11-20
Orange Book patents# Current patent rows page 1 of 1 · 8 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N212194-001 10131907 2028-08-24 U-2672 Drug substance, Drug product 2019-12-12 N212194-001 8828956 2028-12-04 U-2672 Drug substance, Drug product 2019-12-12 N212194-001 8106022 2029-12-12 U-2672 Drug substance, Drug product 2019-12-12 N212194-001 10125364 2033-03-15 U-2672 Drug substance, Drug product 2019-12-12 N212194-001 9631193 2033-03-15 U-2672 2019-12-12 N212194-001 9133461 2033-11-30 U-2672 Drug substance, Drug product 2019-12-12 N212194-001 10119143 2034-10-03 U-2672 Drug substance, Drug product 2019-12-12 N212194-001 11028392 2034-10-03 U-2672 Drug substance, Drug product 2022-02-16
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N212194-001 ODE-273 2026-11-20
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 42 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N212194-001 GIVLAARI EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2019-11-20 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N212194-001 GIVLAARI EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2019-11-20 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 12 · 471 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N212194-001 10131907 2028-08-24 U-2672 Drug substance, Drug product 2019-12-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212194-001 8828956 2028-12-04 U-2672 Drug substance, Drug product 2019-12-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212194-001 8106022 2029-12-12 U-2672 Drug substance, Drug product 2019-12-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212194-001 10125364 2033-03-15 U-2672 Drug substance, Drug product 2019-12-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212194-001 9631193 2033-03-15 U-2672 2019-12-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212194-001 9133461 2033-11-30 U-2672 Drug substance, Drug product 2019-12-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212194-001 10119143 2034-10-03 U-2672 Drug substance, Drug product 2019-12-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N212194-001 11028392 2034-10-03 U-2672 Drug substance, Drug product 2022-02-16 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N212194-001 10131907 2028-08-24 U-2672 Drug substance, Drug product 2019-12-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212194-001 8828956 2028-12-04 U-2672 Drug substance, Drug product 2019-12-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212194-001 8106022 2029-12-12 U-2672 Drug substance, Drug product 2019-12-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212194-001 10125364 2033-03-15 U-2672 Drug substance, Drug product 2019-12-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212194-001 9631193 2033-03-15 U-2672 2019-12-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212194-001 9133461 2033-11-30 U-2672 Drug substance, Drug product 2019-12-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212194-001 10119143 2034-10-03 U-2672 Drug substance, Drug product 2019-12-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N212194-001 11028392 2034-10-03 U-2672 Drug substance, Drug product 2022-02-16 c2088c7a36db…2026-09-14 22:38:34 2026-08 N212194-001 10131907 2028-08-24 U-2672 Drug substance, Drug product 2019-12-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212194-001 8828956 2028-12-04 U-2672 Drug substance, Drug product 2019-12-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212194-001 8106022 2029-12-12 U-2672 Drug substance, Drug product 2019-12-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212194-001 10125364 2033-03-15 U-2672 Drug substance, Drug product 2019-12-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212194-001 9631193 2033-03-15 U-2672 2019-12-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212194-001 9133461 2033-11-30 U-2672 Drug substance, Drug product 2019-12-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212194-001 10119143 2034-10-03 U-2672 Drug substance, Drug product 2019-12-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N212194-001 11028392 2034-10-03 U-2672 Drug substance, Drug product 2022-02-16 84e616aacf4f…2026-08-18 06:07:40 2026-07 N212194-001 10131907 2028-08-24 U-2672 Drug substance, Drug product 2019-12-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212194-001 8828956 2028-12-04 U-2672 Drug substance, Drug product 2019-12-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212194-001 8106022 2029-12-12 U-2672 Drug substance, Drug product 2019-12-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212194-001 10125364 2033-03-15 U-2672 Drug substance, Drug product 2019-12-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212194-001 9631193 2033-03-15 U-2672 2019-12-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212194-001 9133461 2033-11-30 U-2672 Drug substance, Drug product 2019-12-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212194-001 10119143 2034-10-03 U-2672 Drug substance, Drug product 2019-12-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N212194-001 11028392 2034-10-03 U-2672 Drug substance, Drug product 2022-02-16 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N212194-001 10131907 2028-08-24 U-2672 Drug substance, Drug product 2019-12-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212194-001 8828956 2028-12-04 U-2672 Drug substance, Drug product 2019-12-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212194-001 8106022 2029-12-12 U-2672 Drug substance, Drug product 2019-12-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212194-001 10125364 2033-03-15 U-2672 Drug substance, Drug product 2019-12-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212194-001 9631193 2033-03-15 U-2672 2019-12-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212194-001 9133461 2033-11-30 U-2672 Drug substance, Drug product 2019-12-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212194-001 10119143 2034-10-03 U-2672 Drug substance, Drug product 2019-12-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N212194-001 11028392 2034-10-03 U-2672 Drug substance, Drug product 2022-02-16 011fe1cb6892…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 73 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 5 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 71336-1001 GIVLAARI givosiran sodium Alnylam Pharmaceuticals, Inc. NDA Current 71336-1001 GIVLAARI givosiran sodium Alnylam Pharmaceuticals, Inc. NDA Current 71336-1001 GIVLAARI givosiran sodium Alnylam Pharmaceuticals, Inc. NDA Current 71336-1001 GIVLAARI givosiran sodium Alnylam Pharmaceuticals, Inc. NDA Current 71336-1001 GIVLAARI givosiran sodium Alnylam Pharmaceuticals, Inc. NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 78320 SUPPL 2024-04-30 78307 SUPPL 2024-04-30 73497 SUPPL 2023-02-14 73472 SUPPL 2023-02-13 69176 SUPPL 2021-10-29 69154 SUPPL 2021-10-29 61248 ORIG 2019-12-12 61018 ORIG 2019-11-22 60994 ORIG 2019-11-20